论文部分内容阅读
胶质瘤是颅内最常见的原发恶性肿瘤,约占成人原发脑肿瘤的30%,年发病率约为14.7/10万人.虽然在神经外科技术、放射与化学治疗等方面近年已有很大的进展,但胶质瘤的预后并无明显的改善,5年生存率仍<5.5%.近几年,许多学者提出胶质瘤的基因治疗,已有几种基因转移系统利用于局部治疗肿瘤,这些系统利用体外转移基因和细胞因子或大的组织相容性基因来诱导免疫介导的肿瘤消退,而另一种基因治疗方法是用药物敏感基因(“自杀”基因,如HSV—tK基因)来选择性地破坏肿瘤.这些分子生物学方面的进展,给胶质瘤治疗带来新的希望.本文就胶质瘤的单纯疱疹病毒胸腺激酶(HSV—tK)基因治疗综述如下:
Glioma is the most common intracranial primary malignant tumor, accounting for about 30% of adult primary brain tumors, the annual incidence of about 14.7 / 100000. Although in neurosurgical techniques, radiation and chemotherapy in recent years has been But there is no significant improvement in the prognosis of glioma, 5-year survival rate was still <5.5% .In recent years, many scholars put forward the gene therapy of glioma, there are several gene transfer system used in Topical treatment of tumors, which utilize in vitro transfer of genes and cytokines or large histocompatibility genes to induce immune-mediated tumor regression, while another approach to gene therapy uses drug-sensitive genes (“suicide” genes such as HSV -tK gene) to selectively destroy the tumor.These advances in molecular biology have brought new hope for the treatment of glioma.This review summarizes the gene therapy of HSV-tK in glioma :